With initial applications in oncology, the proprietary technology can determine the exact cellular location and amount of specific proteins that manifest in cells, offering an early-stage, highly precise diagnosis and insights into a patient’s disease that can inform research and a clinicians’ treatment plan.
In 2015, Konica Minolta pioneered advanced immunostaining technology – High-Sensitivity Tissue Testing (HSTT) – that uses fluorescent nanoparticles to detect and quantify the proteins that drive disease states and offers far greater precision and accuracy than conventional immunostaining techniques. Leveraging its long history of innovation in materials science, nanofabrication, optics, and imaging, Konica Minolta has developed a comprehensive range of technologies and services in the healthcare field spanning digital X-ray diagnostic imaging systems, diagnostic ultrasound systems, and ICT service platforms for medical institutions.Īmbry’s genetic testing capabilities complement Konica Minolta’s advanced imaging technology to create the most comprehensive range of healthcare diagnostics for use by pharmaceutical companies, healthcare providers, payers, and consumers. The acquisition of Ambry and the advancement of precision medicine marks a strategic and important shift for Konica Minolta’s healthcare business. This will not only serve as the future foundation for our healthcare business, but will pave the way for a fundamental shift in the way medicine is practiced globally.” Together with Ambry, we will have the most comprehensive set of diagnostic technologies for mapping an individual’s genetic and biochemical makeup, as well as the capabilities to translate that knowledge into information the medical community can use to discover, prevent, and cost-effectively treat diseases. “The future of medicine is patient-focused.
#KONICA MINOLTA PRECISION MEDICINE SERIES#
“This acquisition is the first in a series of strategic initiatives to secure a leading position for Konica Minolta in precision medicine”, said Shoei Yamana, President and CEO of Konica Minolta. Konica Minolta plans to bring Ambry’s capabilities first to Japan, and then to Europe.
Precision medicine aims to improve a patients’ quality of life and save the healthcare system money by eliminating unnecessary and ineffective treatments. Konica Minolta views the addition of Ambry as the first stepping-stone to create an exciting new medical platform aimed at fulfilling the potential of precision medicine – an emerging approach to healthcare where genetic or molecular analysis is used to match patients with the most appropriate treatment for their specific disease. Ambry is known as a pioneer and thought leader in genetic testing being the first laboratory in the world to offer such tests as hereditary cancer panels and clinical exome sequencing. They are recognized as a leader in diagnostic solutions for hereditary conditions in the United States, by having performed more than one million genetic tests and identified more than 45,000 mutations in at least 500 different genes. Ambry has the world’s most comprehensive suite of genetic testing solutions for inherited and non-inherited diseases as well as for numerous clinical specialties, including oncology, cardiology, pulmonology, neurology, and general genetics. $800 million will be paid upon closure, and there will be an additional payment of up to $200 million based on certain financial metrics over the next two years, valuing the acquisition up to a total of $1.0 billion.įounded in 1999, Ambry is a privately held healthcare company in the U.S., led by founder, President and Chairman Charles L.M. The transaction is partially funded by Innovation Network Corporation of Japan (INCJ). Konica Minolta and Ambry Genetics Corporation announced the signing of a definitive agreement for a subsidiary of Konica Minolta to acquire Ambry. Advances Konica Minolta strategy to establish a leadership position in precision medicine Contributes to diagnostic solutions in oncology and drug discovery through a combination of Konica Minolta and Ambry Genetics technologies. Introduces the world’s most comprehensive genetic-diagnostic solutions to Japan and other markets.
0 kommentar(er)
